Novo Nordisk Explores Kidney Disease Sector with Epigen Deal

GALWAY, IRELAND--June 4, 2018--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Denmark's pharmaceutical giant Novo Nordisk AS (NYSE:NVO) (Bagsvaerd, Denmark) has agreed to pay up to $200 million in upfront and milestone payments for the worldwide rights to a kidney disease drug in development at San Diego-based Epigen Biosciences.

Within this article: Details Novo's move into kidney sector, Epigen's EPGN696 drug and progress, related Novo Nordisk deals outside of the diabetes sector